Rebecca Robbins

4 days ago | rethinking65.com | Rebecca Robbins

Hundreds of thousands of Americans stand to soon lose their access to cheaper weight-loss drugs, with a federal crackdown on copycat versions threatening to disrupt treatment and raise costs. The Food and Drug Administration has ordered producers and sellers of the less expensive products to wind down operations in the coming weeks now that it has declared there are no longer shortages of the blockbuster drugs Wegovy and Zepbound.

5 days ago | nytimes.com | Teddy Rosenbluth |Rebecca Robbins

An interim U.S. attorney is demanding information about the selection of research articles and the role of N.I.H. Experts worry this will have a chilling effect on publications. A federal prosecutor has sent letters to at least three medical journals accusing them of political bias and asking a series of probing questions suggesting that the journals mislead readers, suppress opposing viewpoints and are inappropriately swayed by their funders.

6 days ago | nytimes.com | Rebecca Robbins |Gina Kolata

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat obesity and diabetes. Encouraging clinical trial results announced on Thursday stand to open up a huge market for a convenient daily pill to treat obesity and diabetes. The experimental drug, developed by Eli Lilly and known as orforglipron, is a type of medication known as a GLP-1.

1 week ago | virginislandsdailynews.com | Rebecca Robbins

Hundreds of thousands of Americans stand to soon lose their access to cheaper weight-loss drugs, with a federal crackdown on copycat versions threatening to disrupt treatment and raise costs. The Food and Drug Administration has ordered producers and sellers of the less expensive products to wind down operations in the coming weeks now that it has declared there are no longer shortages of the blockbuster drugs Wegovy and Zepbound.

1 week ago | nytimes.com | Rebecca Robbins |Dani Blum

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or suspend treatment for patients. Copycat medications, produced through a process of mixing drug ingredients known as compounding, have spawned a multi-billion-dollar industry. Credit... Hilary Swift for The New York Times U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or suspend treatment for patients.